Tag Archives: Boehringer Ingelheim

Love Potion #9: The Hypoactive Sexual Desire Disorder Pipeline

New products in development for women distressed by a lack of sexual desire and satisfying sexual experiences are causing a stir, but not for the reasons one might expect.   Do women have less of a right than men to combat sexual disorders with pills? That’s the question eight national and international women’s advocacy groups […]
Posted in FDA, healthcare, leadership, Market Access, Patient Communication, R&D, Regulatory, Safety, Strategy | Also tagged , , , , , , , , | 1 Comment

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Posted in Corporate Responsibility, Deals, Emerging Markets, Global, IP, Market Access, pricing | Also tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

FDA’s New Breakthrough Designation Process: A Patient Perspective

With the FDA holding its first patient-focused drug development meeting in October of last year, regulators are starting to take notice of the impact disease-based organizations can have in improving drug trial design for new therapies—particularly for rare diseases. According to Teresa Barnes, Vice President of Patient Outreach & Program Support for the Coalition for […]
Posted in FDA, Orphan Drugs, People, R&D, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Also tagged , , , , | 1 Comment

Feds End Use of Seven Inhalers (But Not All At Once)

Image by noii’s via Flickr FDA, on Tuesday, announced that it would phase out the use of seven asthma and chronic obstructive pulmonary disease inhalers to keep in check with regulations banning devices containing chlorofluorocarbons (CFCs). Four of the devices have already been discontinued, and the manufacturers of the remaining devices will have to find […]
Posted in Regulatory, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta